In the BioHarmony Drug Report Database
Tafasitamab
Monjuvi, Minjuvi (tafasitamab) is an antibody pharmaceutical. Tafasitamab was first approved as Monjuvi on 2020-07-31. It is used to treat large b-cell lymphoma diffuse in the USA. It has been approved in Europe to treat large b-cell lymphoma diffuse. The pharmaceutical is active against B-lymphocyte antigen CD19.
Trade Name
|
Minjuvi |
|---|---|
Common Name
|
tafasitamab |
ChEMBL ID
|
CHEMBL4298047 |
Indication
|
large b-cell lymphoma diffuse |
Drug Class
|
Monoclonal antibodies: tumors |
Image (chem structure or protein)
